Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the November 21st expiration. One of the key inputs that goes into the price an option ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries (TA:TEVA) reported a slightly smaller-than-expected fall in ...

View Regeneron Pharmaceuticals, Inc. (REGN) current and estimated P/E ratio data provided by Seeking Alpha.

On Thursday, Evercore ISI adjusted its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN), bringing it down slightly to $1,170 from the previous $1,175, while ...

On March 10, the county legislature approved $6 million for the Pine Hills Land Authority to maintain campus security and infrastructure as revitalization plans unfold.

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Regeneron’s investigational gene therapy has been tied to notable hearing improvements in 10 of 11 children who were treated for a rare genetic condition that causes hearing loss. “You can see ...